Carlos A Morillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6577413/publications.pdf

Version: 2024-02-01

73 papers

10,753 citations

33 h-index 70 g-index

77 all docs

77 docs citations

times ranked

77

10139 citing authors

#	Article	IF	CITATIONS
1	Longitudinal strain by speckle tracking and echocardiographic parameters as predictors of adverse cardiovascular outcomes in chronic Chagas cardiomyopathy. International Journal of Cardiovascular Imaging, 2022, 38, 1245-1255.	1.5	4
2	Atrial Fibrillation Detected After Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. Stroke, 2022, 53, STROKEAHA121034777.	2.0	57
3	Symptom reduction in initial orthostatic hypotension: Time to get physical!. Heart Rhythm, 2022, 19, 611-612.	0.7	O
4	Cardioneuroablation for vasovagal syncope and atrioventricular block: A stepâ€byâ€step guide. Journal of Cardiovascular Electrophysiology, 2022, 33, 2205-2212.	1.7	8
5	Atrial fibrillation after transcatheter patent foramen ovale closure: To measure is to know. Heart Rhythm, 2022, 19, 1421-1422.	0.7	1
6	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace, 2021, 23, 65-72.	1.7	2
7	Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10â€year experience in a single center. Transplant Infectious Disease, 2021, 23, e13549.	1.7	4
8	Low-blood pressure phenotype underpins the tendency to reflex syncope. Journal of Hypertension, 2021, 39, 1319-1325.	0.5	34
9	Incidence of Concurrent Atrial Fibrillation in Patients Who Present With Atrial Tachycardia and Atrial Flutter Postablation for Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008683.	4.8	2
10	Measuring the QT interval on the go. Cardiology Journal, 2021, 28, 358-359.	1.2	0
11	Clinician needs and perceptions about cardioneuroablation for recurrent vasovagal syncope: An international clinician survey. Heart Rhythm, 2021, 18, 2160-2166.	0.7	11
12	Midodrine for the Prevention of Vasovagal Syncope. Annals of Internal Medicine, 2021, 174, 1349-1356.	3.9	37
13	Lack of Equity in the Cardiology Physician Workforce: AÂNarrative Review and Analysis of the Literature. CJC Open, 2021, 3, S180-S186.	1.5	6
14	Completeness of Linear or Fractionated Electrogram Ablation in Addition to Pulmonary Vein Isolation on Ablation Outcome. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010146.	4.8	3
15	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). Open Forum Infectious Diseases, 2021, 8, ofab513.	0.9	4
16	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS ONE, 2021, 16, e0258622.	2.5	6
17	Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 751415.	2.4	1
18	Impact of dual-chamber pacing with closed loop stimulation on quality of life in patients with recurrent reflex vasovagal syncope: results of the SPAIN study. Europace, 2020, 22, 314-319.	1.7	9

#	Article	IF	CITATIONS
19	Circulating <i>Trypanosoma cruzi</i> load and major cardiovascular outcomes in patients with chronic Chagas cardiomyopathy: a prospective cohort study. Tropical Medicine and International Health, 2020, 25, 1534-1541.	2.3	8
20	Effect of Postablation Monitoring Strategy on Long-Term Outcome for Catheter Ablation of Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008682.	4.8	3
21	Association Between Quality of Life and Procedural Outcome After Catheter Ablation for Atrial Fibrillation. JAMA Network Open, 2020, 3, e2025473.	5.9	18
22	Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas. Revista Da Sociedade Brasileira De Medicina Tropical, 2020, 53, e20190477.	0.9	7
23	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	2.3	75
24	Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. Global Heart, 2020, 15, 36.	2.3	4
25	COVID-19: Implications for People with Chagas Disease. Global Heart, 2020, 15, 69.	2.3	39
26	American Trypanosomiasis (Chagas Disease). Infectious Disease Clinics of North America, 2019, 33, 119-134.	5.1	145
27	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European Heart Journal, 2019, 40, 3013-3021.	2.2	125
28	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. Canadian Journal of Cardiology, 2019, 35, 389-395.	1.7	33
29	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATEâ€AF study Clinical Cardiology, 2018, 41, 440-449.	1.8	12
30	Atrial fibrillation ablation long-term outcomes: is there light at the end of the tunnel?. Europace, 2018, 20, 1065-1066.	1.7	0
31	Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC), Journal of the American Society of Echocardiography, 2018, 31, 3-25.	2.8	50
32	2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, 1883-1948.	2.2	1,200
33	Prevention of Arrhythmia Device Infection Trial. Journal of the American College of Cardiology, 2018, 72, 3098-3109.	2.8	160
34	Implantable cardioverter-defibrillator in Chagas heart disease: A systematic review and meta-analysis of observational studies. International Journal of Cardiology, 2018, 267, 88-93.	1.7	11
35	Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2018, 12, e0006567.	3.0	53
36	Measuring Success in Ablation of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006582.	4.8	6

#	Article	IF	Citations
37	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation, 2018, 138, e169-e209.	1.6	315
38	Implantable Cardioverter Defibrillator mHealth App for Physician Referrals and eHealth Education: ICD-TEACH Pilot Study. JMIR Cardio, 2018, 2, e10499.	1.7	3
39	Cardiovascular testing in patients with postural tachycardia syndrome and Ehlers-Danlos type III: authors' response. Clinical Autonomic Research, 2017, 27, 119-120.	2.5	0
40	Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation. JAMA Cardiology, 2017, 2, 812.	6.1	6
41	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. European Heart Journal, 2017, 38, 1339-1344.	2.2	428
42	Cardiovascular profile in postural orthostatic tachycardia syndrome and Ehlers–Danlos syndrome type III. Clinical Autonomic Research, 2017, 27, 113-116.	2.5	13
43	Impact of acute atrial fibrillation termination and prolongation of atrial fibrillation cycle length on the outcome of ablation of persistent atrial fibrillation: A substudy of the STAR AF II trial. Heart Rhythm, 2017, 14, 476-483.	0.7	51
44	Dual-Chamber Pacing With ClosedÂLoopÂStimulation in RecurrentÂReflexÂVasovagal Syncope. Journal of the American College of Cardiology, 2017, 70, 1720-1728.	2.8	102
45	Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy. International Journal of Cardiology, 2017, 227, 577-582.	1.7	24
46	The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Global Heart, 2017, 12, 273.	2.3	35
47	Atrial fibrillation: the current epidemic. Journal of Geriatric Cardiology, 2017, 14, 195-203.	0.2	208
48	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 170-180.	3.2	44
49	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	1.2	34
50	Association of Cardiovascular Disease and Sleep Apnea at Different Altitudes. High Altitude Medicine and Biology, 2016, 17, 336-341.	0.9	8
51	Fludrocortisone for the Prevention ofÂVasovagal Syncope. Journal of the American College of Cardiology, 2016, 68, 1-9.	2.8	116
52	Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?. Current Cardiology Reports, 2016, 18, 71.	2.9	5
53	Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003333.	4.8	149
54	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.7	197

#	Article	IF	Citations
55	Predictors for atrial fibrillation detection after cryptogenic stroke. Neurology, 2016, 86, 261-269.	1.1	153
56	Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. European Heart Journal, 2016, 37, 1493-1498.	2.2	96
57	2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm, 2015, 12, e41-e63.	0.7	694
58	Syncope and Driving. Cardiology Clinics, 2015, 33, 465-471.	2.2	10
59	Approaches to Catheter Ablation for Persistent Atrial Fibrillation. New England Journal of Medicine, 2015, 372, 1812-1822.	27.0	1,725
60	Sudden cardiac death: improving our pathological diagnosis-are we there yet?. Europace, 2014, 16, 785-786.	1.7	1
61	Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). JAMA - Journal of the American Medical Association, 2014, 311, 692.	7.4	533
62	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation, 2014, 129, 2094-2099.	1.6	579
63	Cryptogenic Stroke and Underlying Atrial Fibrillation. New England Journal of Medicine, 2014, 370, 2478-2486.	27.0	1,694
64	Cytokine Profiling in Chagas Disease: Towards Understanding the Association with Infecting Trypanosoma cruzi Discrete Typing Units (A BENEFIT TRIAL Sub-Study). PLoS ONE, 2014, 9, e91154.	2.5	65
65	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. Open Cardiovascular Medicine Journal, 2014, 8, 113-120.	0.3	18
66	Discerning the Incidence of Symptomatic and Asymptomatic Episodes of Atrial Fibrillation Before and After Catheter Ablation (DISCERN AF). JAMA Internal Medicine, 2013, 173, 149.	5.1	267
67	Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. American Heart Journal, 2013, 165, 558-566.	2.7	44
68	Nitroglycerine in HUTT - An explosion in Our Understanding of Unexplained Syncope?. Indian Pacing and Electrophysiology Journal, 2013, 13, 200-202.	0.6	0
69	Age-Dependent Effect of \hat{I}^2 -Blockers in Preventing Vasovagal Syncope. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 920-926.	4.8	68
70	Evaluation and Treatment of Chagas Disease in the United States. JAMA - Journal of the American Medical Association, 2007, 298, 2171.	7.4	654
71	The Effect of Sham Feeding on Neurocardiac Regulation in Healthy Human Volunteers. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 721-726.	1.7	7
72	Prevention of Syncope Trial (POST). Circulation, 2006, 113, 1164-1170.	1.6	256

#	Article	lF	CITATIONS
73	Current management of syncope: Treatment alternatives. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 371-383.	0.9	10